MED29

Across TCGA pan-cancer cohorts, MED29 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated MED29 data layer compared with 3 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher MED29 RNA is associated with better overall survival. In most high-consensus cancer types, elevated MED29 expression acts as an unfavorable survival marker, although some lineages such as KIRC and BRCA show a favorable association.

KIRC, UVM, and BRCA are the cancer types where MED29 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Tertile	All	0.740	0.517	<.001	112	view →
UVM	DFS	Median	All	0.325	0.657	<.001	109	view →
BRCA	OS	Tertile	All	0.961	0.900	<.001	72	view →
SCLC	DFS	Tertile	All	0.544	0.280	.005	46	view →
LIHC	DFS	Quartile	All	0.400	0.604	<.001	26	view →
UCS	DFS	Tertile	III,IV	0.677	0.208	<.001	26	view →
CHOL	OS	Tertile	All	0.892	0.165	.004	24	view →
READ	OS	Tertile	All	0.955	0.306	.004	18	view →
LGG	OS	Tertile	All	0.743	0.855	.003	17	view →
SKCM	OS	Quartile	All	0.807	0.966	<.001	16	view →
ACC	OS	Quartile	II,III,IV	1.000	0.460	.017	12	view →
LAML	DFS	Quartile	All	0.453	0.677	.015	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

MED29–KIRC (OS)

Open the KIRC breakdown →